Session » Immunological Complications of Therapy Poster (1516–1529)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1521

Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events

8:30AM-10:30AM: Abstract Number: 1528

Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration

8:30AM-10:30AM: Abstract Number: 1516

Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients

8:30AM-10:30AM: Abstract Number: 1519

Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers

8:30AM-10:30AM: Abstract Number: 1524

COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population

8:30AM-10:30AM: Abstract Number: 1526

Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy

8:30AM-10:30AM: Abstract Number: 1520

Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?

8:30AM-10:30AM: Abstract Number: 1527

Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis

8:30AM-10:30AM: Abstract Number: 1529

Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy

8:30AM-10:30AM: Abstract Number: 1518

Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study

8:30AM-10:30AM: Abstract Number: 1523

Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution

8:30AM-10:30AM: Abstract Number: 1522

Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis

8:30AM-10:30AM: Abstract Number: 1517

Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade

8:30AM-10:30AM: Abstract Number: 1525

Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].